<DOC>
	<DOCNO>NCT00143806</DOCNO>
	<brief_summary>The purpose study devise safe effective method transition patient cyclosporine alefacept .</brief_summary>
	<brief_title>Transitioning From Cyclosporine Alefacept Psoriasis</brief_title>
	<detailed_description>The purpose study devise safe effective method transition patient cyclosporine alefacept . Patients study well control cyclosporine desire switch alefacept . The study do three phase . In Phase 1 ( 12 week duration ) two drug overlap , cyclosporine slowly taper . Both drug discontinue 12 week . In Phase 2 ( 12 week duration ) , patient drug . In Phase 3 ( 24 week long ) , patient second course alefacept alone 12 week 12 week . Topical UV light treatment allow throughout study . Total length study one year .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Inclusion Criteria Adult psoriasis patient ( 18 80 year old ) , well control cyclosporine ( Static PGA score mild , minimal clear ) need desire stop cyclosporine start alefacept . Exclusion Criteria CD4 &lt; 400 Active infection ( trivial URI , etc . ) History AIDS Hepatitis B , C Inability understand consent comply study requirement Pregnancy Lactation History heart liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>cyclosporine</keyword>
	<keyword>transition</keyword>
	<keyword>alefacept</keyword>
</DOC>